ImmunityBio Inc.

IBRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.15

-$0.14 (-1.69%)

Nov 2, 2026, 10:28 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ALLO Allogene Therapeutics	N/A
ATRA Atara Biotherapeutics	N/A
BNTX BioNTech SE	N/A
IMCR Immunocore plc	N/A
IMTX Immatics	N/A
IOVA Iovance Biotherapeutics	N/A
LEGN Legend Biotech	N/A
MRNA Moderna	N/A
NKTX Nkarta	N/A
VIR Vir Biotechnology	N/A

Dividend Rankings ➞

Recent News

14 days ago / benzinga.com
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
17 days ago / businesswire.com
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
18 days ago / zacks.com
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
18 days ago / benzinga.com
ImmunityBio Stock Climbs Thursday: What's Going On?
25 days ago / businesswire.com
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
1 month ago / benzinga.com
ImmunityBio Stock Jumps: What's Going On?
2 months ago / zacks.com
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
2 months ago / zacks.com
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
2 months ago / seekingalpha.com
ImmunityBio: None Of The Moonshots Is Priced In
3 months ago / businesswire.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman